Tauriga Sciences, Inc. Shares Included in The Marijuana Index
Leading Cannabis Related Index to Continually Supply Market Info and Analysis for Tauriga Sciences, Inc.
LOS ANGELES, CALIFORNIA — (Tues. February 24, 2015 ) – Tauriga Sciences, Inc. (OTCQB: TAUG) or (“Tauriga” or “the Company”) announced today that it has been selected by The Marijuana Index (“the index”) (www.marijuanaindex.com) for inclusion in its MJIC Reporting Company Index. Because of the Company’s transparency and fully reporting status, The Marijuana Index has further elected to list Tauriga on a superior tier of the index.
The Marijuana Index is the leading equity tracking index featuring public companies involved in the cannabis industry. The Marijuana Index provides the most robust data set in the industry with a perpetually expanding assemblage of information available to brokers, analysts, investors and media.
For more information regarding Tauriga Sciences, Inc. and its standing in The Marijuana Index please visit www.marijuanaindex.com.
“We are pleased to have shares of Tauriga included in The Marijuana Index where our corporate story can be followed by a larger number of parties interested in our industry,” said Dr. Stella M. Sung, Chief Executive Officer. “As more companies enter this dynamic industry, it is both a privilege and an opportunity to be tracked as a leading public company in the legal cannabis industry. This will allow our shareholders access to real-time industry data and an expansive set of tools to better follow our company and industry developments.”
“We view the inclusion of Tauriga Sciences, Inc. in the Index as an important step in providing further legitimacy to public company cannabis operations,” stated Frank Marino, President of MJIC, Inc. “Investors in this quickly growing industry deserve and appreciate as much information as possible and we intend to continue to supply data and market intelligence for Tauriga in perpetuity.”
Tauriga recently manufactured its CannaCaviar line of cannabidiol (CBD) soft gels, which will be available for sale later this week. The Company also sells a proprietary topical medicinal cannabis cream branded as TopiCanna. Many who have used topical cannabis creams have reported decreased musculoskeletal pain. Both TopiCanna and CannaCaviar are designed to provide potential natural wellness and healing properties without psychoactive effects, and the key ingredient for both products is cannabidiol (CBD) oil from non-GMO industrial hemp. In addition, Tauriga has launched a non-cannabis containing line of natural wellness dietary supplements. These natural supplements include IndiCalm, natural calming formula without inducing cognitive impairment; ClearNaze, a natural decongestant without stimulant or drowsiness effects; Satietiva, an amino acid-based appetite suppressant; and MendWCan, a highly pure, potent and palatable Omega 3 supplement. For more information on Tauriga’s natural wellness product line, please visit www.taurigastore.com.
About The MJIC Marijuana Index
The MJIC Marijuana Index measures the combined performance of globally listed marijuana stocks. The Indices are calculated by using an equally weighted algorithm, providing a standardized and balanced calculation methodology. The index provides existing and prospective investors with a targeted and centralized view of these pioneering securities which are positioned within a multi-billion dollar growth industry. Information and articles are shared from around the web on the business of marijuana as it unfolds throughout the United States and the world. The mission of The Marijuana Index is to become the centralized hub of communication between cannabis companies and the investment marketplace following the industry.
The Marijuana Index is the leading benchmark for tracking publicly traded marijuana stocks as the first industry specific equity index of its kind.
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company’s corporate website at www.tauriga.com and the Company’s e-commerce website at www.taurigastore.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
Dr. Stella M. Sung,
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
San Diego: + 1-858-353-5749
Montreal: + 1-514-840-3697